This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frederiksen, L. J. Articles by Graham, C. H. Search for Related Content PubMed PubMed Citation Articles by Frederiksen, L. J. Articles by Graham, C. H.

Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling

Authors' Affiliations: Departments of ¹ Anatomy and Cell Biology, ² Urology, and ³ Pharmacology and Toxicology, Queen's University, Kingston, Ontario, Canada

Requests for reprints: Charles H. Graham, Department of Anatomy and Cell Biology, Botterell Hall, Room 859, Queen's University, Kingston, Ontario, Canada K7L 3N6. Phone: 613-533-2852; Fax: 613-533-2566; E-mail: grahamc{at}post.queensu.ca.

Purpose: Hypoxia contributes to drug resistance in solid cancers, and studies have revealed that low concentrations of nitric oxide (NO) mimetics attenuate hypoxia-induced drug resistance in tumor cells in vitro. Classic NO signaling involves activation of soluble guanylyl cyclase, generation of cyclic GMP (cGMP), and activation of cGMP-dependent protein kinase. Here, we determined whether chemosensitization by NO mimetics requires cGMP-dependent signaling and whether low concentrations of NO mimetics can chemosensitize tumors in vivo.

Experimental Design: Survival of human prostate and breast cancer cells was assessed by clonogenic assays following exposure to chemotherapeutic agents. The effect of NO mimetics on tumor chemosensitivity in vivo was determined using a mouse xenograft model of human prostate cancer. Drug efflux in vitro was assessed by measuring intracellular doxorubicin-associated fluorescence.

Results: Low concentrations of the NO mimetics glyceryl trinitrate (GTN) and isosorbide dinitrate attenuated hypoxia-induced resistance to doxorubicin and paclitaxel. Similar to hypoxia-induced drug resistance, inhibition of various components of the NO signaling pathway increased resistance to doxorubicin, whereas activation of the pathway with 8-bromo-cGMP attenuated hypoxia-induced resistance. Drug efflux was unaffected by hypoxia and inhibitors of drug efflux did not significantly attenuate hypoxia-induced chemoresistance. Compared with mice treated with doxorubicin alone, tumor growth was decreased in mice treated with doxorubicin and a transdermal GTN patch. The presence of GTN and GTN metabolites in plasma samples was confirmed by gas chromatography.

Conclusion: Tumor hypoxia induces resistance to anticancer drugs by interfering with endogenous NO signaling and reactivation of NO signaling represents a novel approach to enhance chemotherapy.

This article has been cited by other articles:

				R. Sullivan, G. C. Pare, L. J. Frederiksen, G. L. Semenza, and C. H. Graham Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity Mol. Cancer Ther., July 1, 2008; 7(7): 1961 - 1973. [Abstract] [Full Text] [PDF]

				D. R. Siemens, N. Hu, A. K. Sheikhi, E. Chung, L. J. Frederiksen, H. Pross, and C. H. Graham Hypoxia Increases Tumor Cell Shedding of MHC Class I Chain-Related Molecule: Role of Nitric Oxide Cancer Res., June 15, 2008; 68(12): 4746 - 4753. [Abstract] [Full Text] [PDF]